Clindamycin + Tobramycin

The combination of clindamycin and tobramycin is an antibiotic regimen used primarily for treating serious infections, particularly intra-abdominal infections and septic peritonitis. This combination leverages the complementary antimicrobial spectra of both drugs to provide broad coverage against both aerobic and anaerobic pathogens. Clindamycin is a lincosamide antibiotic effective against anaerobic bacteria, streptococci, staphylococci, and pneumococci[5]. Tobramycin is an aminoglycoside antibiotic with activity against gram-negative organisms, particularly Pseudomonas aeruginosa, and some gram-positive bacteria[3]. The combination has been studied extensively in clinical settings, with research showing efficacy in treating serious infections including septic peritonitis, intra-abdominal sepsis, and infections in immunocompromised patients such as those with leukemia[1][4][9]. ## Dosing Information Standard dosing for this combination typically includes: - **Tobramycin**: 1.5 mg/kg body weight every 8 hours (for serious infections) or up to 5 mg/kg/day in divided doses for life-threatening infections[1][6] - **Clindamycin**: 0.9 g every 8 hours[1] For patients with impaired renal function, tobramycin dosage adjustments are necessary, with monitoring of serum concentrations recommended[6]. ## Clinical Applications This antibiotic combination has been used successfully in: - Septic peritonitis and intra-abdominal sepsis[1] - Febrile episodes in leukemic patients[4] - Serious infections in patients with cystic fibrosis (with adjusted dosing)[6] - Prophylaxis in elective colorectal surgery (using a single high dose of tobramycin)[10] ## Side Effects and Monitoring Common side effects observed with this combination include: - Diarrhea - Skin reactions - Potential for ototoxicity and nephrotoxicity (primarily from tobramycin) - Risk of superinfection (e.g., Candida albicans)[1] Monitoring recommendations include: - Tobramycin serum concentration determinations - Renal function tests - Monitoring for auditory and vestibular toxicity, especially for treatment courses longer than 10 days[6] ## Comparative Efficacy Studies have compared this combination with other antibiotic regimens. One study comparing ceftazidime/clindamycin versus tobramycin/clindamycin for intra-abdominal infections found that ceftazidime/clindamycin more effectively eradicated bacteria, though clinical response rates were similar[9]. This combination represents an important therapeutic option for serious infections, particularly when broad-spectrum coverage against both aerobic and anaerobic pathogens is required.